Department of Pharmaceutical Sciences, School of Pharmacy, The University of Texas El Paso, El Paso, TX 79902, United States; Department of Biomedical Engineering, The University of Texas El Paso, El Paso, TX 79968, United States.
Department of Pharmaceutical Sciences, School of Pharmacy, The University of Texas El Paso, El Paso, TX 79902, United States.
J Control Release. 2022 Nov;351:504-559. doi: 10.1016/j.jconrel.2022.09.024. Epub 2022 Sep 30.
Among the various dosage forms, oral medicine has extensive benefits including ease of administration and patients' compliance, over injectable, suppositories, ocular and nasal. Despite of extensive demand and emerging advantages, over 50% of therapeutic molecules are not available in oral form due to their physicochemical properties. More importantly, most of the biologics, proteins, peptide, and large molecular drugs are mostly available in injectable form. Conventional oral drug delivery system has limitation such as degradation and lack of stability within stomach due to presence of highly acidic gastric fluid, hinders their therapeutic efficacy and demand more frequent and higher dosing. Hence, formulation for controlled, sustained, and targeted drug delivery, need to be designed with feasibility to target the specific region of gastrointestinal (GI) tract such as stomach, small intestine, intestine lymphatic, and colon is challenging. Among various oral delivery approaches, mucoadhesive vehicles are promising and has potential for improving oral drug retention and controlled absorption to treat local diseases within the GI tract, as well systemic diseases. This review provides the overview about the challenges and opportunities to design mucoadhesive formulation for oral delivery of therapeutics in a way to target the specific region of the GI tract. Finally, we have concluded with future perspective and potential of mucoadhesive formulations for oral local and systemic delivery.
在各种剂型中,口服药物具有广泛的优势,包括给药方便和患者依从性好,优于注射剂、栓剂、眼用和鼻用制剂。尽管需求广泛,且具有新兴优势,但由于其物理化学性质,超过 50%的治疗性分子无法制成口服剂型。更重要的是,大多数生物制剂、蛋白质、肽和大分子量药物主要以注射剂的形式存在。由于胃内存在高酸性胃液,常规口服药物递送系统存在局限性,如在胃内降解和缺乏稳定性,这会影响其治疗效果,并需要更频繁和更高的剂量。因此,需要设计用于控制、持续和靶向药物递送的制剂,以实现针对胃肠道(GI)特定区域的靶向,如胃、小肠、肠淋巴和结肠,这具有挑战性。在各种口服递送方法中,黏膜黏附载体具有很大的发展潜力,可以提高口服药物的保留率,并控制其在胃肠道内的吸收,以治疗局部疾病和全身疾病。本文综述了设计用于治疗胃肠道特定区域的黏膜黏附制剂的挑战和机遇。最后,我们对黏膜黏附制剂在口服局部和全身递送上的未来前景和潜力进行了总结。
J Control Release. 2022-11
Curr Pharm Des. 2021
Drug Deliv Transl Res. 2021-4
J Pharm Pharm Sci. 2003
Methods Mol Biol. 2019
Pharmaceuticals (Basel). 2025-7-24
AAPS PharmSciTech. 2025-6-3
Gels. 2025-4-4
Drug Deliv Transl Res. 2025-3-20
World J Gastroenterol. 2022-5-14
Biomater Sci. 2022-5-31
Polymers (Basel). 2022-3-21
J Control Release. 2022-5